The price of a drug should be based on the value it brings to patients and society. A drug like Zolgensma is undervalued by drug price debators. Aducanumab if approved by FDA should not be allowed to have a high price because of questionable/marginal benefit.
-
-
-
Whoever comes up with the formula that calculates the value so that we can find the “right” price might win a Nobel Prize. Until then, we can take comfort that most drugs go generic and work on ensuring that all do.
Kraj razgovora
Novi razgovor -
-
-
it's almost like you should have put it in ... a book
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
-
-
hospital administrators' pay vs physician and nurse pay is another value discrepancy
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.